Yes. When ordered as part of a documented treatment plan, LCMS toxicology testing is a covered benefit under Medicare, Medicaid, and most commercial insurance plans. Results Diagnostics handles all billing directly. Your facility pays nothing and manages no claims.
Immunoassay point-of-care testing — the cup tests most programs use — was not designed for clinical decision-making. It screens for drug classes, not specific compounds. It generates false positives on over-the-counter medications. It cannot detect Xylazine, most designer benzodiazepines, or confirm whether a patient is actually taking their medication.
Results Diagnostics uses liquid chromatography-mass spectrometry (LCMS) — the same methodology used by medical review officers, forensic laboratories, and federal drug testing programs. Every result is identified to the specific compound, quantified, and documented in a legally defensible chain of custody.
Buprenorphine and Norbuprenorphine are reported separately. The ratio of parent drug to metabolite is the gold standard for confirming true ingestion versus diversion. A screen-only result cannot make this distinction. Ours can.
Xylazine is present in the illicit fentanyl supply in every major market in the country. It is not detectable on standard immunoassay screens. Our panel detects it. Most labs do not test for it at all.
Standard immunoassay screens routinely miss designer benzodiazepines — clonazolam, etizolam, flualprazolam, and others that are increasingly common in the illicit supply. We identify all 11 benzodiazepines by name.
The full fentanyl family — fentanyl, norfentanyl, acetylfentanyl, carfentanil — plus all major opioids. The most comprehensive opiate panel available.
Ethyl glucuronide and ethyl sulfate detect alcohol use up to 80 hours after consumption — well beyond the window of a standard breathalyzer or BAC test. Critical for programs that serve alcohol use disorder patients or have zero-tolerance policies.
SSRIs, SNRIs, tricyclic antidepressants, antipsychotics, and anticonvulsants — confirms medication adherence and detects diversion among patients on dual-diagnosis treatment plans.
Increasingly misused, rarely tested. Our panel detects both.
Nothing. Laboratory testing is a covered benefit under Medicare, Medicaid, and most commercial insurance plans when ordered as part of a documented treatment plan. Results Diagnostics bills the patient’s insurance directly. Your facility does not receive an invoice, manage claims, or front any costs.
| Service | Cost to Facility |
|---|---|
| LCMS testing and processing | $0 |
| Collection supplies and requisition forms | $0 |
| Results delivery and portal access | $0 |
| Dedicated account representative | $0 |
| Monthly clinical report | $0 |
| Long-term contract | Not required |
Behavioral health programs face increasing scrutiny from state licensing boards, CARF, The Joint Commission, and Medicaid managed care organizations. Documentation requirements are tightening. Audit exposure is real.
Immunoassay results are not audit-defensible. They cannot identify specific compounds, do not distinguish between substances in the same drug class, and carry a false positive rate of 5–10%.
LCMS results are — by definition — confirmatory. Every positive is specific, quantified, and documented with a full chain of custody. When a licensing board, payer, or attorney asks for documentation of your drug monitoring program, LCMS results hold up.
Day 0: Sign the Lab Services Agreement — 30-day termination clause, no lock-in.
Days 1–2: We deliver your supply kit — collection cups, chain of custody forms, custom requisition forms printed with your facility name.
Days 3–5: Kickoff call — confirm panel, pickup schedule, results delivery. 15 minutes.
Days 7–10: In-person staff training at your facility. 30 minutes. Every staff member leaves with a direct number for your account representative.
Day 30: First monthly clinical report — your facility’s data, analyzed, with panel utilization and positivity trends summarized for your clinical team.
Ongoing: Quarterly in-person check-ins. Proactive supply management. Direct line to the lab — not a call center.
Standard results are returned within 24 hours of specimen receipt. Critical results — including unexpected positives for fentanyl, Xylazine, or high-risk substances — are called directly to the ordering clinician the same day.
No. Our Lab Services Agreement includes a 30-day termination clause. We earn your business every month.
Results Diagnostics is enrolled as a Medicaid provider in Nevada and our target states. We bill Medicaid directly for all covered testing. Your facility is not involved in the billing process and does not receive any claims or invoices.
Immunoassay cup tests screen for drug classes and generate a positive or negative result. LCMS identifies every substance to the specific compound, quantifies the amount present, and provides a result that is legally and clinically defensible. For a behavioral health program, the difference is the difference between guessing and knowing.
Yes. Xylazine is included in our standard panel. Most commercial labs do not test for it. If your patients are in a market where fentanyl is present — which is every major market — Xylazine is in the supply chain.
Yes. Every Results Diagnostics client has one named contact with a direct phone number. That person knows your facility, your panel, and your preferences. There is no call center.
Results Diagnostics is CLIA-certified (CLIA # 29D2310339) and COLA-accredited (COLA # 33493). COLA accreditation requires an on-site inspection and ongoing compliance review — it is a voluntary, peer-reviewed standard that goes beyond the federal CLIA baseline. We also participate in CAP proficiency testing programs.
Contact our team.
Phone: 702-830-5100
Email: info@results-dx.com
Address: 5580 S. Fort Apache Rd, Unit 120, Las Vegas, NV 89148
Results Diagnostics LLC | CLIA # 29D2310339 | NPI # 1063253094
Copyright © 2025 Results Diagnostics – All Rights Reserved.
